Access to healthcare

We partner with academic institutions, research hospitals, not-for-profits and companies at the forefront of discovering life-saving therapies to improve human health, with funding solutions tailored to the needs of our partners.

Accelerating innovation in life sciences

Partner of choice for funding life sciences innovation

We work with a wide range of partners across the biopharma ecosystem and are currently the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the industry.

How a particular medicine will positively impact human health is of critical importance and the lens through which we examine each investment opportunity.

Brienne Kugler,
Senior Vice President, Research & Investments

Robust due diligence

Investing in therapies that transform patient lives globally

Our ultimate goal is to invest in therapies that transform patient lives globally, making responsible business considerations an important part of our process.

We have developed a robust framework to guide our decision-making and management practices, collaborating with key external partners and leveraging our data capabilities to identify and analyze sustainability-related risks and opportunities before making an investment.

Social Bond Framework

Social investments that positively impact human health

In 2021, we issued social bonds under our Social Bond Framework, consisting of $600 million fixed-rate 10-year notes. Eligible investments advanced our broader ESG initiatives and contributed to SDG 3 (Good Health and Well-being) and SDG 9.5 (Enhance Scientific Research, Encourage Innovation).

Building on our commitment to diversity, equity and inclusion, the co-managers for our social bonds included minority- and women-owned business enterprises and service-disabled veteran-owned business firms.

See how we are improving access to healthcare

Cystic Fibrosis Foundation:
funding new innovative therapies

Our initial $3.3 billion royalty acquisition of Kalydeco, Orkambi, Symdeko, Trikafta provided capital that allowed the foundation to more than double funding to develop new lifesaving therapies and support cystic fibrosis (“CF”) patient care.

“These new funds give us a tremendous opportunity to supercharge our efforts to develop lifesaving new therapies, ensure that the best possible care and resources are available for people with CF, and pursue daring, new opportunities that one day may lead to a permanent, lifelong cure for this disease.”

Robert J. Beall,
Ph.D.; Cystic Fibrosis Foundation Former President and CEO

Memorial Sloan Kettering Cancer Center:
enabling the development of a new research facility

Our $405 million royalty acquisition of Neupogen / Neulasta, a stimulant of white blood cell production that is used to reduce the risk of infection for cancer patients receiving various forms of chemotherapy, provided capital to MSKCC to reinvest in cancer research, expand its footprint and build one of the largest research centers in New York.

“The net proceeds from this sale will be used to reinvest in MSKCC’s basic and translational research programs and facilities, which we hope will produce new discoveries that will benefit our patients and cancer patients elsewhere.”

John Gunn,
Executive Vice President

Additional funding to improve access to healthcare:

pre-approval funding in Trodelvy, now approved for metastatic triple negative breast cancer and metastatic urothelial cancer
pre-approval funding in Nurtec ODT, now approved for migraine

Stay up to date

Subscribe to Royalty Pharma news and alerts